Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, outlined the 2 pipeline drugs she is keeping a close eye on in 2016: both are breakthrough therapies and one could have a significant impact on the market.
Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, outlined the 2 pipeline drugs she is keeping a close eye on in 2016: both are breakthrough therapies and one could have a significant impact on the market.
Transcript (slightly modified)
What drugs in the pipeline are most exciting to you? What will you be watching in 2016?
Ocrelizumab is one. So this is a biologic drug for MS. And it's going to be the first MS drug approved for primary progressive
There are a few drugs that I'm watching this year that I think are really interesting. MS. So that's about 15% of the MS population is diagnosed with primary progressive MS. And right now there is nothing FDA approved to treat these patients. It's been given a breakthrough therapy designation. It's an IV infusion, once every 6 months. And in a primary progressive trial it slowed disease progressive by 25% compared to placebo. So it seems like a very effective option. That's expected to be approved later this year, probably late December.
Another drug that I am watching is dupilumab. This may be approved in early 2017. It inhibits interleukins 4 and 13 for atopic dermatitis. So it would be reserved for patients with moderate to severe atopic dermatitis who can't be well controlled on currently available therapies, like the calcineurin inhibitors or topical corticosteroids. But this population is very huge—up to 1.6 milion Americans have more severe atopic dermatitis with no real good treatment options for them. So now we'll have a biologic drug that's given every 2 weeks by subcutaneous injections. It's very effective in clinical trials—a breakthrough therapy. I don't know how much it will cost, but my guess is somewhere around $20,000 a year. And if that's used in a large patient population chronically, it could have a really significant impact on the market.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More